is a biopharmaceutical company that specializes in researching, developing and commercializing innovative medicines. The company has achieved an impressive performance, outperforming the S&P 500 by a significant 45.5 per cent. It’s the top performer of our list. Gilead Sciences generates 60 per cent of its revenue from HIV treatments, which form a resilient portion of its portfolio.
Investors are advised to do further research before investing in any of the companies listed in the accompanying table.Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: CTVNews - 🏆 1. / 99 続きを読む »